Safe-C

Safe-C is a Danish biotechnology company focused on the development of next-generation inhibitors of the complement system. The company's primary focus is on targeting Complement component 3 (C3), a central hub in the complement cascade, to treat a variety of inflammatory and autoimmune disorders. Safe-C's lead candidates are designed to offer improved safety and efficacy profiles compared to first-generation C3 inhibitors. The company leverages the extensive research of its founders in complement biology to address high unmet needs in conditions such as paroxysmal nocturnal hemoglobinuria and geographic atrophy. Safe-C is currently in the pre-clinical stage of development, advancing its lead peptide-based inhibitors toward clinical trials.